Addendum
Addendum to Commission A13-44 (ipilimumab, new therapeutic indication)
Report documents
-
Addendum
Addendum to Commission A13-44 (ipilimumab, new therapeutic indication)
Press releases
Ipilimumab in advanced melanoma: added benefit for non-pretreated patients still not proven
In two addenda, IQWiG conducted an assessment of study data on further comparator therapy and on updated data analyses
Project details
- Project no.
- A14-11
- Commission
- Commission awarded on 11.03.2014 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Skin and hair
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Addendum
Second Addendum to Commission A13-44 (ipilimumab, new therapeutic indication)
Status: Commission completed
-
Dossier assessment
Ipilimumab (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed